---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-017380"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:45:28.180756+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma Q2 2022 cash $89.3M; initiates Phase 3 sarcoidosis study

## Summary
- Cash, restricted cash, cash equivalents and investments $89.3M as of June 30, 2022.
- R&D expenses $9.1M, G&A expenses $3.4M for Q2 2022; no revenue reported.
- First sites initiated in global Phase 3 EFZO-FIT study for pulmonary sarcoidosis.
- FDA Fast Track designation granted for efzofitimod in pulmonary sarcoidosis.
- Company on track to enroll first patient in Q3 2022; 28.1M shares outstanding.

## SEC filing metadata
- accession: 0000950170-22-017380
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017022017380/0000950170-22-017380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017022017380/life-20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-017380
- JSON: https://secwatch.observer/filing/0000950170-22-017380.json
- Plain text: https://secwatch.observer/filing/0000950170-22-017380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.